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E-mail address: bart.staels@pasteur-lille.fr (B. StaeFarnesoid X receptor (FXR) is highly expressed in liver and intestine where it controls bile acid (BA),
lipid and glucose homeostasis. Here we show that FXR is expressed and functional, as assessed by
target gene expression analysis, in human islets and b-cell lines. FXR is predominantly cytosolic-
localized in the islets of lean mice, but nuclear in obese mice. Compared to FXR+/+ mice, FXR/
mice display a normal architecture and b-cell mass but the expression of certain islet-speciﬁc genes
is altered. Moreover, glucose-stimulated insulin secretion (GSIS) is impaired in the islets of FXR/
mice. Finally, FXR activation protects human islets from lipotoxicity and ameliorates their secretory
index.
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Type 2 diabetes is characterized by the progressive deteriora-
tion of b-cell secretory function and its capacity to compensate
for increased peripheral insulin resistance [1].
Nuclear receptors are transcription factors that regulate glucose
and lipid metabolism in a variety of metabolically active tissues,
including the pancreatic b-cell [2]. The farnesoid X receptor (FXR;
NR1H4), which is highly expressed in liver, intestine and adrenal
glands, is a receptor of bile acids (BA) [3–5]. BA-activated FXR pro-
tects the liver from BA-overload by controlling the transcription of
genes responsible for their synthesis, biotransformation and cellu-chemical Societies. Published by E
umin; FGF, ﬁbroblast growth
id X receptor; GSIS, glucose-
eptide; IPGTT, intraperitoneal
ncreatic duodenal homeobox
d receptor (a,d,c); SHP, small
des; VLDL-R, very low density
INSERM UMR1011, 1, rue du
ls).lar excretion [6]. FXR also modulates hepatic lipid and lipoprotein
metabolism. Recent data identiﬁed a role for FXR in glucose
homeostasis [7]. FXR gene expression is induced by glucose in rat
hepatocytes, whereas insulin reversed this effect [8]. Moreover,
FXR mRNA levels are increased in livers of diabetic db/db mice
[9]. Treatment of type 2 diabetic dyslipidaemic patients, with
intestinal-acting bile acid sequestrants, such as cholestyramine
or colesevelam, resulted in lower plasma glucose and HbA1C con-
centrations [10]. Several authors suggested that BA decrease hepa-
tic glucose production by the liver and therefore improve
hyperglycemia by regulating enzymes of gluconeogenesis [11–
13]. In addition, FXR/mice display impaired glucose and insulin
tolerance due to blunted insulin signaling pathways in skeletal
muscle and white adipose tissue [13,14]. Moreover, treatment with
GW4064 enhances insulin sensitivity in db/db [13] and ob/ob mice
[14], suggesting that FXR agonists could be promising therapeutic
agents for type 2 diabetes treatment.
In our previous studies, we have speculated that the decreased
clearance of plasma glucose observed in FXR/ mice upon
intraperitoneal glucose tolerance test (IPGTT) could be explained,
besides the peripheral insulin resistance, by an impaired insulin
secretion of the pancreas [14]. In order to investigate thislsevier B.V. All rights reserved.
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cells and whether it participates in the regulation of glucose
homeostasis by the b-cell. Our results show that FXR is expressed
and active in b-cells and pancreatic islets, both in rodents and hu-
mans. Using islets isolated from FXR/mice or human islets trea-
ted with FXR ligands, we show that FXR controls the proper
response of b-cells to a glucose challenge and that FXR activation
protects human islets under lipid-induced metabolic stress.2. Materials and methods
2.1. Cell culture
Rat INS1E and mouse bTC6 pancreatic b-cells were routinely
maintained in RPMI1640 medium (Gibco, Invitrogen) supple-
mented with 1 mM sodium pyruvate, 2 mM L-glutamine, 100 mM
gentamycine, 50 lM b-mercaptoethanol, 10% FCS and incubated
at 37 C in 5% CO2.E
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See Supplementary data.
2.3. Animals
All studies performed with laboratory animals were approved
by the institutional review boards for the care and use of experi-
mental animals. Lean C57Bl6/J wild type and ob/ob male mice were
obtained from Charles Rivers Laboratory (France). Homozygous
FXR/ and sex- and age-matched FXR+/+ littermates, bred on
the C57Bl6/J genetic background, housed in a pathogen-free barrier
facility with 12 h light/12 h dark cycle, were maintained on a stan-
dard laboratory chow diet (A03/R03).
2.4. Mouse and human islet isolation
Mouse pancreatic islets were obtained by the collagenase
digestion method [15], adapted as described in Supplementary, OB/OB
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elsewhere [16]. The human islets used in this study were isolated
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See Supplementary data.
2.6. Islet morphometry
It was determined as described in [16]. Measurement of the
area of pancreatic islets, as well as that of total pancreatic sections,
was manually performed using Image J software [17].
2.7. Immunodetection of FXR
Immunodetection was performed according to the method of
Higashiyama et al. [18], modiﬁed as described in Supplementary
data.
2.8. Gene expression
Total RNA was isolated from pancreatic tissue using the guanid-
inium thiocyanate (GSCN)/phenol/chloroform extraction method
and from cells using the Trizol reagent (EuroBio) and subsequently
reverse-transcribed into cDNA with the Superscript II kit (Applied
Bioscience). mRNA levels of the analyzed genes were quantiﬁedFXR+/+ FXR-/-
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Fig. 5. FXR-deﬁciency results in altered expression of genes encoding islet hormones
transcription factors (B) was analyzed by Q-PCR in the pancreas of FXR/ vs. FXR+/+ mby real-time quantitative PCR using the DNA Master Mix Syber
Green II kit and speciﬁc primers listed in Table 1 (Supplementary
data). mRNA levels were normalized to house keeping genes as
indicated in the ﬁgures.
2.9. Statistics
Results are expressed as indicated in the ﬁgure legend. Un-
paired Student’s t-test was used for measuring the statistical sig-
niﬁcance of differences between two groups. P < 0.05 was
considered of statistical signiﬁcance (*P < 0.05, **P < 0.01,
***P < 0.001).
3. Results
3.1. FXR is expressed and active in pancreatic islets and b-cell lines
FXR mRNA was detected in mouse pancreas and isolated mouse
islets (average Ct = 28 and 26.5, respectively) (Fig. 1A and B) as
well as in bTC6 (average Ct = 27.8) and INS1E cells (average
Ct = 27.3) (Fig. 1C). Interestingly, unlike in the liver, FXR protein
is localized in the extranuclear compartment of islets of lean mice
(FXR+/+, OB/OB), whereas in obese mice (FXR+/+, ob/ob), FXRIn
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tern blot in INS1E b-cells (Fig. 1E).
To determine whether FXR is active in the pancreas, the expres-
sion of small heterodimer partner (SHP) and very low density lipo-
protein-receptor (VLDL-R), two positively regulated FXR target
genes in the liver [7], was analyzed by Q-PCR in the pancreas of
FXR/ vs. FXR+/+ mice (Fig. 2A). VLDL-R mRNA was signiﬁcantly
lower in the pancreas of FXR /mice, whereas SHP mRNA tended
to be lower in FXR/ mice (P = 0.06). To determine whether FXR
is active in b-cells, INS1E cells were treated with the speciﬁc FXR
agonists GW4064 and CDCA. Both agonists induced the expression
of SHP and VLDL-R mRNA (Fig. 2B).
3.2. FXR-deﬁciency does not modify the architecture and morphometry
of pancreatic islets
FXR/ mice display no apparent morphological abnormalities
of the pancreas. However, at 20 weeks of age, basal (after 6 h of
fasting) blood glucose and insulin levels of FXR/mice were low-
er compared with FXR+/+ mice (117 ± 10 vs. 176 ± 7 mg/dL and
1.00 ± 0.1 vs. 1.83 ± 0.35 lg/L, respectively). Although the hypogly-Fig. 6. FXR is expressed and functional in human islets. (A) Expression proﬁle of severa
homeobox gene-1 (PDX-1) mRNA expression, set at 1. The values were normalized to T
(PPARc), 27.6 (peroxisome proliferator-activated receptor d, PPARd), 29.2 (FXR), 27.9 (live
for 48 h with RPMI containing GW4064 or CDCA (mean ± S.E.; n = 3). The average Ct valu
(C), apoptosis (D), low- and high-GSIS and the stimulation index (E) of human islets incub
serum albumin (BSA) (white bars) for 48 h. Results correspond to 40IE (islet equivalentcemia of FXR/mice can explain their lower basal insulinemia, a
modiﬁed architecture or a b-cell mass defect of the pancreas in
FXR/ mice could also contribute to this. To verify this hypothe-
sis, islet morphometric analysis was performed in FXR/ vs. +/+
mice (Fig. 3A). Islet surface was not different between FXR/
and FXR+/+ mice. The b-cell mass, calculated as the number of is-
lets per pancreatic surface, was also equivalent between FXR/
and FXR+/+ mice. In addition, staining with antibodies against glu-
cagon and insulin evidenced that the organization of a- and b-cells
was preserved in FXR/ compared to FXR+/+ islets (Fig. 3B).
3.3. Glucose-stimulated insulin secretion (GSIS) is impaired in islets
isolated from FXR/ mice
To study the functionality of the islets of FXR/ mice, inde-
pendent of any systemic inﬂuences, size-matched islets isolated
from 20 to 25 weeks-old FXR/ and FXR+/+ mice were incubated
in the presence of low (2.8 mM) and high (20 mM) glucose concen-
trations (Fig. 4A). The insulin response of FXR/ islets to high
glucose was signiﬁcantly reduced compared to that of FXR+/+ mice
(P < 0.01). Consequently, the capacity of individual islets to secretel nuclear receptors in human pancreatic islets, compared with pancreatic duodenal
FIIb mRNA level (mean ± S.E.; n = 3). The average Ct values are: 28.8 (PPARa), 31.8
r X receptor b, LXRb), 26 (PDX-1). (B) FGF-19 mRNA level in human islets incubated
es obtained for FGF-19 are: 27.5 (DMSO), 24 (GW4064) and 26 (CDCA). TG content
ated with FXR agonists and palmitate 0.33 mM (black bars) or fatty acid-free bovine
) and to 1 h of static incubation (mean ± S.E.; n = 3). *P < 0.05 and ***P < 0.001.
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islets (insulinogenic index = 2.66 vs. 4.57, respectively). The total
insulin content of non-stimulated FXR/ islets was also signiﬁ-
cantly lower compared with that of FXR+/+ islets (Fig. 4B).
3.4. The expression of b-cell markers is altered in the pancreas of
FXR/ mice
The defect in GSIS of FXR/ islets suggested that b-cells lack-
ing FXR display abnormalities in glucose-sensing and/or in the cas-
cade of glucose metabolism. mRNA levels of two b-cell speciﬁc
hormones, insulin and islet amyloid polypeptide (IAPP), were low-
er in FXR/mice (Fig. 5A). A signiﬁcant decrease of somatostatin
(SST) mRNA was also observed in the FXR/ mice, but no alter-
ation in the expression of glucagon was seen (data not shown).
Therefore, we examined the expression of b-cell transcription
factors that are necessary for glucose-sensing and stimulation of
insulin secretion by the mature, differentiated b-cell (Fig. 5B). MafA
and PDX-1 mRNA expression, two master transcription factors reg-
ulating the insulin gene and GSIS in the mature b-cell [19], were
decreased in FXR/ pancreas. mRNA levels Beta2/NeuroD1, a
key transcription factor of islet cells [20], were also reduced in
FXR/ pancreas, while mRNA level of Nkx6.1, a transcription fac-
tor primarily expressed in adult b-cells [21] was not modiﬁed.
3.5. FXR activation protects human pancreatic islets from lipotoxicity
FXR mRNA was found to be expressed in human islets isolated
from three brain-dead donors at a level similar to that of the nucle-
ar receptor peroxisome proliferator-activated receptor a (PPARa),
but higher than peroxisome proliferator-activated receptor c
(PPARc) (Fig. 6A). When human islets were exposed in vitro to
the FXR agonists GW4064 (5 lM) or CDCA (50 lM), the expression
of FGF-19 mRNA, a positively regulated FXR target gene in humans
[22], increased signiﬁcantly in the presence of both agonists, albeit
to a larger extent with the synthetic ligand GW4064 (Fig. 6B). This
result suggests that FXR is also active in human islets.
Incubation of the islets with GW4064 (5 lM) or CDCA (50 lM)
decreased triglyceride accumulation and improved the viability of
islets exposed to palmitate (Fig. 6C and D). Consistently, activation
of FXR with GW4064 or CDCA improved the stimulation index of
the human islets (Fig. 6E). Interestingly, this effect was not due
to an increase of insulin secretion after high glucose stimulation
(20 mM), but rather to a normalization of insulin secretion at low
glucose (2.8 mM) (Fig. 6E). In the islets not exposed to palmitate,
activation of FXR did not inﬂuence these parameters.4. Discussion
In the present study we show that FXR mRNA and protein is ex-
pressed in mouse and human islets and in b-cell lines. Q-PCR anal-
ysis revealed that C57Bl6 mice signiﬁcantly express FXR in the
pancreas. FXR expression in isolated islets, although less important
than in the liver, is comparable to that in adipose tissue (average
Ct = 29.01), where FXR plays a regulatory role [14]. Recently, Chu-
ang et al. screened the expression of nuclear receptors in the endo-
crine pancreas and found the presence of FXR mRNA [23]. While
our study was in progress, Renga et al. reported the expression of
FXR in bTC6 cells and human islets where its activation has posi-
tive effects on insulin secretion [24]. Interestingly, we found that
in mouse islets, FXR seems to be localized in the cytoplasmic com-
partment, whereas it translocates, under metabolic stress condi-
tions such as insulin resistance and obesity, to the nucleus.
FXR/mice do not display on altered islet area or b-/a-cell distri-
bution, suggesting that FXR is not required for the maintenance ofislet architecture or b-cell mass in mice under normal diet condi-
tions. However, analysis of the expression of several speciﬁc islet
hormones and transcription factors revealed decreased levels in
FXR/ pancreases. PDX-1, MafA and Beta2/NeuroD1 contribute
to both b-cell speciﬁc and glucose-responsive insulin gene tran-
scription by interacting with cis-regulatory elements located in
the promoter of the (pro)insulin gene [19] and interact with each
other to regulate b-cell function [25].
Whole body FXR/ mice display complex alterations in glu-
cose and lipid metabolism since FXR-deﬁciency inﬂuences metab-
olism in several organs (i.e. liver, adipose tissue) [7]. To study the
tissue-autonomic function of FXR in the endocrine pancreas inde-
pendently of other systemic inﬂuences, GSIS tests were performed
on isolated islets of both genotypes. The secretory capacity of the
islets (insulinogenic index) was decreased in FXR/ vs. FXR+/+ is-
lets. In addition, the total insulin content of isolated FXR/ islets
was also reduced, suggesting that the observed hypoinsulinaemia
of FXR/ mice after 6 h of fasting is not solely due to reduced li-
ver glucose output and plasma glucose levels in these mice.
Since FXR is nuclear localized in the endocrine cells of ob/ob
mice, FXR could play a role in b-cell function under lipid-stress
conditions. Indeed, treatment of human islets with FXR agonists
protects islets from palmitate-induced triglycerides (TG) accumu-
lation and apoptosis. In addition, we found that FGF-19, a member
of the FGF-family, is expressed and induced by FXR agonists in hu-
man islets. Indeed, ﬁbroblast growth factor (FGF) signaling is re-
quired for a proper glucose-sensing in mouse b-cells [26] and in
human HepG2 cells, where FGF-19 has an inhibitory effect on fatty
acid synthesis induced by insulin [27]. Whether this mechanism
occurs also in human b-cells, remains to be established.
In conclusion, our study identiﬁes a role for FXR in the control of
islet function and opens promising new perspectives for the pre-
vention of type 2 diabetes.
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